Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

June

22

TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors

PERIO-1 and PERIO-2 studies evaluating integration of SD-101 and PEDD administration DENVER and CHICAGO,...

9

Exagen Inc. Expands Coverage with MediNcrease

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

24

electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company,...

16

Exagen Inc. Expands Coverage with Alivio Health

Partnership to provide more accurate diagnostic testing with AVISE® CTD and AVISE® Lupus SAN...

11

Exagen Inc. Reports First Quarter 2022 Results

Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly...

11

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

10

TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial

Studying the delivery of SD-101 via pressure-enabled drug delivery in adults with hepatocellular carcinoma...

5

electroCore Announces Record First Quarter 2022 Financial Results

First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially...

5

ATEC Reports First Quarter 2022 Financial Results and Increases Full-Year Revenue Guidance

Revenue growth of 61%, including organic revenue growth of 39% EOS imaging revenue of...

1

Exagen Announces Five-Week Campaign for Lupus Awareness Month

Weekly themes to focus on diagnosis, advocacy, community, research, and motivation SAN DIEGO, May 01,...

21

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

Evaluation results indicate nVNS therapy may potentially improve the course of patients’ COVID-19 symptoms...

19

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program

If initial findings are confirmed, program calls for field-ready gammaCore™ nVNS devices in 2H-2023 ROCKAWAY,...

Recent developments

News

June

22

TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors

June

9

Exagen Inc. Expands Coverage with MediNcrease

May

24

electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

May

16

Exagen Inc. Expands Coverage with Alivio Health

May

11

Exagen Inc. Reports First Quarter 2022 Results

May

11

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

May

10

TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial

May

5

electroCore Announces Record First Quarter 2022 Financial Results

May

5

ATEC Reports First Quarter 2022 Financial Results and Increases Full-Year Revenue Guidance

May

1

Exagen Announces Five-Week Campaign for Lupus Awareness Month

April

21

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

April

19

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program